Small Molecule Drug Discovery

We strive to push the boundaries of AI for drug discovery by continuously inventing and integrating innovations across machine learning, biology and chemistry.

Our AI-designed proprietary drug MDR-001, an oral small-molecule GLP-1 RA, obtained US IND approval in 19 months since program initiation, for the treatment of obesity and type 2 diabetes mellitus.

Discover New
Drugs Together

Cooperations with biopharma in AI-enabled drug discovery with a focus on Hard-to-Drug molecular targets.

MindRank has successfully delivered an allosteric inhibitor PCC with Best-in-Class potential to a public traded biotech company.

Molecule Pro™

By leveraging our proprietary AI platform, we aim to significantly accelerate the drug discovery process and deliver small molecule drugs with superior potency, druggability, and novelty.

Turning low-probability events into high-probability events through systematic engineering and platform-based approaches.

A Scientific Driven Team

MindRank consists of over 30 scientists from top biopharma and global AI competition winners. The team has rich industrial experience and success stories in drug hunting and technological innovations with AI.

Some of the innovations were published in venues such as Nature Biomedical Engineering, Patterns (Cell Press), Advanced Science and ICML, IJCAI, KDD.

The company's proprietary AI solution was nominated by Deep Pharma Intelligence as one of the "Top AI Breakthroughs in Biopharma from 2018 to 2020".